{"id":"colloidal-bismuth-subcitrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Darkening of stool/tongue (bismuth discoloration)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The bismuth component binds to ulcer bases and damaged mucosa, creating a physical barrier that protects against acid and pepsin while promoting healing. Additionally, bismuth has direct bactericidal effects against H. pylori, making it effective in eradication regimens. The subcitrate formulation enhances bioavailability and reduces systemic bismuth absorption.","oneSentence":"Colloidal bismuth subcitrate forms a protective coating over gastric and duodenal ulcers while also exhibiting antimicrobial activity against Helicobacter pylori.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:04.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peptic ulcer disease (gastric and duodenal ulcers)"},{"name":"Helicobacter pylori eradication as part of combination therapy"},{"name":"Functional dyspepsia"}]},"trialDetails":[{"nctId":"NCT07010744","phase":"NA","title":"Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Akil Al Islam","startDate":"2025-07-01","conditions":"Dyspepsia","enrollment":66},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT07260006","phase":"NA","title":"Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","status":"RECRUITING","sponsor":"Can Tho University of Medicine and Pharmacy","startDate":"2024-10-01","conditions":"Helicobacter Pylori Infection, Peptic Ulcer","enrollment":80},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT07146594","phase":"PHASE4","title":"Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Athens Medical Center","startDate":"2025-08-20","conditions":"Helicobacter Pylori Gastritis, Helicobacter Eradication","enrollment":150},{"nctId":"NCT03897244","phase":"PHASE4","title":"Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-05-30","conditions":"Helicobacter Pylori Infection","enrollment":603},{"nctId":"NCT03365609","phase":"NA","title":"A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children","status":"RECRUITING","sponsor":"Ying HUANG","startDate":"2017-09-20","conditions":"Helicobacter Infections","enrollment":1440},{"nctId":"NCT06687473","phase":"PHASE4","title":"Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-01-01","conditions":"Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor","enrollment":13},{"nctId":"NCT06687499","phase":"PHASE4","title":"14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-08-22","conditions":"Helicobacter Pylori, Drug Resistance, Multiple","enrollment":46},{"nctId":"NCT06509139","phase":"PHASE4","title":"Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-07-09","conditions":"Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy","enrollment":661},{"nctId":"NCT04527055","phase":"PHASE4","title":"The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Dysbiosis, Probiotics","enrollment":312},{"nctId":"NCT06216639","phase":"","title":"Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection","status":"UNKNOWN","sponsor":"National Institute of Public Health, Slovenia","startDate":"2024-02-01","conditions":"Helicobacter Pylori Infection","enrollment":2000},{"nctId":"NCT06143124","phase":"PHASE4","title":"Bismuth Quadruple Therapy Versus Standard Triple Therapy","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2022-03-03","conditions":"Helicobacter Pylori Infection","enrollment":216},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-08-01","conditions":"Helicobacter Pylori Infection","enrollment":126},{"nctId":"NCT04853875","phase":"PHASE4","title":"ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2021-04-19","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT05002595","phase":"","title":"H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2018-01-01","conditions":"H. Pylori Infection","enrollment":270},{"nctId":"NCT04122287","phase":"PHASE4","title":"Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-11-01","conditions":"Helicobacter Pylori Infection","enrollment":250},{"nctId":"NCT04264663","phase":"PHASE4","title":"Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-11-01","conditions":"Helicobacter Pylori Infection","enrollment":250},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT04566211","phase":"NA","title":"Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy.","status":"UNKNOWN","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Helicobacter Pylori Infection","enrollment":440},{"nctId":"NCT03716622","phase":"PHASE4","title":"A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2018-07-31","conditions":"Helicobacter Pylori","enrollment":350},{"nctId":"NCT02490839","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT04359966","phase":"NA","title":"Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia","status":"UNKNOWN","sponsor":"Slovenian Society for Gastroenterology and Hepatology","startDate":"2020-05-10","conditions":"Helicobacter Pylori Infection, Eradication Treatments","enrollment":560},{"nctId":"NCT04101708","phase":"PHASE4","title":"A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-09-20","conditions":"Helicobacter Pylori","enrollment":100},{"nctId":"NCT02547038","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-02","conditions":"Helicobacter Pylori Infection","enrollment":352},{"nctId":"NCT03968302","phase":"PHASE2","title":"ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2018-06-01","conditions":"Helicobacter Pylori Infection","enrollment":196},{"nctId":"NCT03925818","phase":"NA","title":"Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication","status":"TERMINATED","sponsor":"Università degli Studi di Sassari","startDate":"2017-08-29","conditions":"Helicobacter Pylori Infection","enrollment":99},{"nctId":"NCT02483715","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":589},{"nctId":"NCT03321773","phase":"NA","title":"Comparing the Efficacy of 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2017-01","conditions":"Helicobacter Pylori Infection","enrollment":440},{"nctId":"NCT02894268","phase":"PHASE4","title":"Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2016-02","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT01712711","phase":"PHASE2","title":"Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-09","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":40},{"nctId":"NCT01654549","phase":"PHASE2","title":"Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-04","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":40},{"nctId":"NCT02541864","phase":"NA","title":"Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2013-07","conditions":"Helicobacter Pylori Infection","enrollment":330},{"nctId":"NCT01906879","phase":"PHASE4","title":"Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-06","conditions":"Helicobacter Pylori Infection","enrollment":1620},{"nctId":"NCT03146325","phase":"PHASE4","title":"Helicobacter Pylori and Body Iron in Adults","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-11","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT03108287","phase":"PHASE4","title":"Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2013-04-01","conditions":"Helicobacter Pylori Infection","enrollment":162},{"nctId":"NCT00669955","phase":"PHASE3","title":"Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06","conditions":"Helicobacter Infections","enrollment":440},{"nctId":"NCT00712413","phase":"PHASE3","title":"Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori","status":"WITHDRAWN","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT01306786","phase":"NA","title":"Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":800},{"nctId":"NCT01876108","phase":"PHASE2","title":"The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-07","conditions":"Fatty Liver, Liver Dysfunction, Insulin Resistance","enrollment":100},{"nctId":"NCT01759628","phase":"PHASE2","title":"Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-04","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":100},{"nctId":"NCT01760824","phase":"NA","title":"Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2011-05","conditions":"Helicobacter Pylori Infection","enrollment":391},{"nctId":"NCT00003151","phase":"PHASE2","title":"Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-09","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT01335334","phase":"PHASE4","title":"H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study","status":"UNKNOWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-03","conditions":"H. Pylori Infection","enrollment":50},{"nctId":"NCT00520949","phase":"NA","title":"Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2006-10","conditions":"Treatment of Helicobacter Pylori","enrollment":176}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"PYREXIA"},{"count":1,"reaction":"ADVERSE EVENT"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"VISION BLURRED"},{"count":1,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":359,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PIDI"],"phase":"marketed","status":"active","brandName":"Colloidal Bismuth Subcitrate","genericName":"Colloidal Bismuth Subcitrate","companyName":"Sir Run Run Shaw Hospital","companyId":"sir-run-run-shaw-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Colloidal bismuth subcitrate forms a protective coating over gastric and duodenal ulcers while also exhibiting antimicrobial activity against Helicobacter pylori. Used for Peptic ulcer disease (gastric and duodenal ulcers), Helicobacter pylori eradication as part of combination therapy, Functional dyspepsia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}